Skip to main content
Clinical Trials/NCT03667729
NCT03667729
Completed
Not Applicable

The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia: Randomized Controlled Trials

Taipei Medical University0 sites75 target enrollmentJune 30, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Affective Disorders
Sponsor
Taipei Medical University
Enrollment
75
Primary Endpoint
Quality of life simplified Chinese versions of the WHOQOL-BREF questionnaire were used
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study applied a randomized parallel case-controlled design. The study purpose was to evaluate the effects of progressive muscle relaxation on anxiety, psychiatric symptoms and quality of life among patients with chronic schizophrenia compared with an active control.

Detailed Description

Background: Anti-psychotic drugs are limited in their ability to improve psychiatric symptoms, quality of life, and anxiety status in patients with chronic schizophrenia. Progressive Muscle Relaxation (PMR) can potentially reduce anxiety status and improve subjective welling in acute patients. It is an ideal rehabilitation intervention for patients with chronic schizophrenia. However, no study has investigated the effects of PMR on outcomes among patients with chronic schizophrenia. Design: This study applied a randomized parallel case-controlled design. Methods: Hospital-based randomized control trial in Taiwan. Eighty subjects with chronic schizophrenia were recruited from a psychotic ward and randomized into PMR, or control groups. Patients in the intervention group participated in progressive muscle relaxation for 12 weeks; while patients in the control group members received supportive treatment-as-usual (TAU). All participants completed anxiety, psychotic syndromes and quality of life measures at baseline, 3-month, and 3-month follow-up.

Registry
clinicaltrials.gov
Start Date
June 30, 2014
End Date
June 29, 2015
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Schizophrenia
  • Without the risk of self-injury and violence
  • Patients aged from 20-65 years old
  • Had no alcohol and drug abuse
  • Can use Mandarin or Taiwanese to communicate

Exclusion Criteria

  • Patients with another psychiatric comorbidity
  • Patients with musculoskeletal problems
  • patients who cannot sit last for 50 minutes
  • Had received progressive muscle relaxation training within the last year
  • Diagnosis of confirmed cardiovascular disease

Outcomes

Primary Outcomes

Quality of life simplified Chinese versions of the WHOQOL-BREF questionnaire were used

Time Frame: Measuring changes in quality of life from baseline to 6 months.

a 28-item questionnaire rated on a five-point Likert scale with four domains measuring: psychological health, physical health, social relationships and environment.so that higher scores refer to high QOL.

Secondary Outcomes

  • Positive and Negative Syndrome Scale (PANSS)(measured at baseline, 3-month, and 3-month follow-up)
  • Anxiety Scale(measured at baseline, 3-month, and 3-month follow-up)

Similar Trials